Status:
TERMINATED
Efficacy of High Flow Therapy in COPD At Home
Lead Sponsor:
Johns Hopkins University
Conditions:
COPD
Eligibility:
All Genders
18-100 years
Brief Summary
Preliminary data show that in COPD patients, HFT substantially decreases ventilatory demand during sleep. The central hypothesis of this proposal is that lowering ventilatory demand using nasal high-f...
Eligibility Criteria
Inclusion
- 1\. Consenting adults over the age of 18 with COPD
Exclusion
- 1\. Apnea Hypopnea Index\>15 events/hr 2. Use of Non-invasive positive pressure ventilation (CPAP + Bilevel) 3. Severe bilateral nasal obstruction (apparent mouth breathing at rest) 4. Documented clinical cardiovascular disease, as defined below:
- myocardial infarction in past 3 months
- revascularization procedure in past 3 months
- implanted cardiac pacemaker or ICD
- unstable arrhythmias
- congestive heart failure with ejection fraction \< 40%
- uncontrolled hypertension (BP \> 190/110) 5. History of end stage renal disease (on dialysis) 6. History of end stage liver disease, such as:
- <!-- -->
- Jaundice
- ascites
- history of recurrent gastrointestinal bleeding
- transjugular intrahepatic portosystemic shunt (TIPS) ; 7. Transportation industry worker (commercial truck or bus drivers, airline pilots) 8. Known pregnancy (by self report) 9. Known coagulopathy or anticoagulant use (e.g. coumadin) other than aspirin. 10. Do you take medications for any of the following reasons:
- <!-- -->
- Pain control (besides NSAIDs)
- Sleep medication
- Benzodiazepines
- Methadone
Key Trial Info
Start Date :
August 15 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 13 2015
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT02230020
Start Date
August 15 2013
End Date
December 13 2015
Last Update
August 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21224